COVID-19 vaccine effectiveness studies in Nigeria: Quo vadis?

Akande, Oluwatosin Wuraola; Igumbor, Ehimario Uche; Elimian, Kelly Osezele; Ohonsi, Cornelius Ehizokhai; Nwozor, Lilian; Oden, Okanke; Ekpenyong, Emmanuel Nsa; Ndodo, Nnaemeka; Ike, Ifeanyi F; Egede, Magdalene; +6 more... Nwachukwu, William; Onoja, Amedu M; Fofah, Jenson Gawain; Azi, Reuben Ishiaku; Ochu, Chinwe L; Adetifa, Ifedayo M; (2022) COVID-19 vaccine effectiveness studies in Nigeria: Quo vadis? Journal of global health, 12. 03055-. ISSN 2047-2978 DOI: https://doi.org/10.7189/jogh.12.03055

Abstract

The “lickety-split” development of COVID-19 vaccines 326 days from when the SARS-COV-2 virus was first sequenced is indeed one of the public health successes of the 21st century. Particularly because an 18-month target was initially considered reasonable, and having achieved this success, a “moonshot” goal to ensure that a vaccine is available within 100 days after the next pandemic pathogen is recognized has been set [1].

Additional Information

Item Type	Article
Faculty and Department	Faculty of Epidemiology and Population Health > Dept of Infectious Disease Epidemiology
Research Centre	Covid-19 Research
PubMed ID	35916589
Elements ID	181871